Previous 10 | Next 10 |
2023-10-04 06:31:10 ET More on Teva Teva considering potential sale of inflammatory bowel disease asset - Bloomberg Teva: Focus On Innovation And Growth Means The Times They Are A Changing The Mighty Teva Pharmaceutical: Unveiling A Bullish Scenario You Must Consider...
TEV ‘574, a novel anti-TL1A therapy, is being developed to treat ulcerative colitis and Crohn’s disease Collaboration supports Sanofi’s immunology strategy of exploring novel mechanisms of action for chronic inflammatory diseases Collaboration leverages the innovative...
2023-10-03 08:10:37 ET More on Johnson & Johnson Johnson & Johnson: The Bull Case Can No Longer Be Ignored Johnson & Johnson: A Very Cautious 'Buy' Johnson & Johnson's Reinvention - Is A New Logo Enough? Johnson & Johnson posts Phase 3 win...
2023-09-29 11:00:14 ET Summary Shares of Amicus Therapeutics declined after FDA approval of Pombiliti and Opfolda for late-onset Pompe disease due to a worse-than-expected label. The label states that only patients not improving on existing treatments are eligible for Pombiliti an...
2023-09-26 07:49:48 ET More on Regeneron Seeking Alpha’s Quant Rating on Regeneron Pharmaceuticals Financial information for Regeneron Pharmaceuticals Regeneron Pharmaceuticals: Game-Changing Discoveries In Healthcare Regeneron Gets Boost With FDA Appr...
If approved, Dupixent would be the first and only treatment in the U.S. indicated for children aged 1 to 11 with EoE, a disease driven by type 2 inflammation that impacts the ability to eat Of the approximately 21,000 children under the age of 12 in the U.S. currently being treated for ...
2023-09-24 12:00:08 ET More on COVID vaccine makers Moderna: Covid Curse Pfizer, Moderna And COVID Vaccine Patents: Implications Of Legal Cases Novavax: Sell A Covid Bounce Barclays projects over $5B COVID booster sales in fall 2023 Vaccine makers...
2023-09-21 14:55:48 ET Summary Analysts have soured on Moderna's prospects, despite recent good news in its drug pipeline. This put spread strategy risks $4.53 to make $0.47 in 121 days. The full premium is earned if MRNA remains above $75 on January 19th, 2024. ...
2023-09-21 09:26:27 ET Summary The French Pharma company is moving on an immunology franchise. Dupixent is the internal cash cow to drive lower debt and internal progress in the early-stage pipeline. Attractive valuation with a P/E discount and potential for upside driven by E...
2023-09-17 12:00:54 ET The impact of COVID, flu, and RSV on U.S. and U.K. hospitals is expected to be lower this winter compared to last, as there won't be a significant overlap between peak outbreaks of infections, the London-based data analytics firm Airfinity said in a recent report. ...
News, Short Squeeze, Breakout and More Instantly...
Sanofi ships U.S. influenza vaccines for the 2024/25 season PR Newswire Customers will start receiving shipments from July 10 with additional shipments through October to healthcare provider offices, pharmacies and other immunizers to support fall immunization campaigns. ...
2024-07-09 06:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...